銘柄コードINBX
会社名インヒブルクス・バイオサイエンス
上場年月日2024/05/29
設立日2024
代表者Mr. Mark Paul Lappe
マーケットナスダック
従業員数172
会計年度末12-31
所在地11025 North Torrey Pines Road,Suite 140
都市La Jolla
州California
国米国
郵便番号92037
電話番号1-858-795-4220
URLhttp://www.inhibrx.com
紹介Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while
